Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Malin ( (MLLNF) ) just unveiled an announcement.
Malin Corporation plc reported its 2024 full-year results, highlighting a strategic divestment from CG Oncology and Poseida, which generated substantial cash proceeds. The company’s intrinsic equity value per share increased due to these transactions, and a significant capital return of up to €150 million was announced via a tender offer. The sale of Poseida to Roche marked a pivotal strategic achievement, while Malin continues to hold valuable interests in Poseida’s technology through contingent value rights. The company’s cash position improved significantly, enabling the proposed capital return, and Malin remains focused on maximizing value from its life sciences investments.
More about Malin
Malin Corporation plc is a company investing in highly innovative life sciences companies. Its primary focus is on creating shareholder value through strategic investments and divestments in the life sciences sector.
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $197.2M
For a thorough assessment of MLLNF stock, go to TipRanks’ Stock Analysis page.
